Aptargroup, Inc. · NYSE:ATR
Aptargroup — Q4 2023 Earnings Presentation
11 slides from Aptargroup's earnings presentation, Feb 9, 2024
Slide 1: Q4 and Full Year 2023 Results
February 9, 2024 Q4 and Full Year 2023 Results Stephan Tanda, President & CEO and Bob Kuhn, Executive Vice President and CFO APTAR COMMUNICATIONS GUIDEBOOK
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q4 2023 Financial Highlights
Q4 2023 Financial Highlights Highlights: +5% Reported Sales Growth +2% Core Sales Growth* • Significant margin improvement driven by a strong focus on cost management across the company as well as rapid growth in the pharma end markets • Achieved an adjusted EBITDA margin within the raised long-term
Slide 4: Full Year 2023 Financial Highlights
Full Year 2023 Financial Highlights Highlights: +5% Reported Sales Growth* +3% • Achieved annual sales of $3.5 billion, with sales growth driven evenly by favorable product mix, volume growth and pricing Core Sales Growth* • Overall, 2023 was a pivotal year filled with many accomplishments. With an
Slide 5: Recent Innovations and Solutions on the Market
Recent Innovations and Solutions on the Market Aptar Pharma Aptar Beauty Aptar Closures • Aptar’s unidose is the nasal delivery system for a • Aptar’s customizable and interchangeable • Aptar’s new closure provides an instant mixing recently launched nasal spray rescue treatment for fragrance pump i
Slide 6: Fourth Quarter 2023 Reported Results
Fourth Quarter 2023 Reported Results Q4 Highlights • Aptar Pharma’s performance was driven by strong double- digit core sales growth for proprietary drug delivery systems used for emergency medicines, allergic rhinitis, central nervous system therapeutics, as well as eye care, nasal saline rinses, a
Slide 7: Fourth Quarter 2023 Adj. EPS and Adj. EBITDA
Fourth Quarter 2023 Adj. EPS and Adj. EBITDA * Adjustments: • 2022: Restructuring Initiatives of $3.6 mil; Net investment loss of $1 mil • 2023: Restructuring Initiatives of $25.4 mil; Net investment loss of $0.4 mil; Transaction costs related to acquisitions of $0.2 mil The prior year’s adjusted ea
Slide 8: Full Year 2023 Reported Results
Full Year 2023 Reported Results Full Year Highlights • Achieved annual sales of $3.5 billion, with sales growth driven evenly by favorable product mix, volume growth and pricing • Reported net income increased 19% to $284 million and adjusted EBITDA increased 15% to $708 million • Margin improvement
Slide 9: Full Year 2023 Adj. EPS and Adj. EBITDA
Full Year 2023 Adj. EPS and Adj. EBITDA Adjusted FY EBIDTA* Adjustments: • 2022: Restructuring Initiatives of $6.6 mil; Net investment loss of $2.1 mil; Realized gain of $1.2 mil included in the net investment loss; Transaction costs related to acquisitions of $0.2 mil • 2023: Restructuring Initiati
Slide 10: Outlook
Outlook Outlook Highlights Earnings Per Share • Intend to build on the positive momentum from $1.40 the previous year and anticipate starting the $1.20 $1.10 – $1.18 24.5-26.5% year off strong in the first quarter $1.00 $0.96 • Expect demand of Pharma’s proprietary drug $0.80 $0.82 Q1 Expected deliv
Slide 11: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 11